NuGen Medical Devices Announces NHS Drug Tariff Approval for EziAutoJector(R) Product Line in the UK
NuGen Medical Devices (TSXV: NGMD) has achieved a significant milestone as its UK distribution partner, EziAutoJector Ltd, received NHS Drug Tariff approval for its needle-free insulin delivery device. This approval means UK diabetes patients can receive the EziAutoJector device and accessories at no cost through NHS-funded care.
The company has established distribution channels through a major pharmaceutical wholesaler for both high-street and online pharmacies. The initiative includes educational programs targeting healthcare professionals and a direct-to-consumer e-commerce channel. Notably, each patient switching to EziAutoJector eliminates over 1,000 single-use insulin needles annually, supporting NHS environmental and cost-efficiency goals.
NuGen Medical Devices (TSXV: NGMD) ha raggiunto un traguardo significativo poiché il suo partner di distribuzione nel Regno Unito, EziAutoJector Ltd, ha ottenuto l'approvazione NHS Drug Tariff per il suo dispositivo di somministrazione di insulina senza aghi. Questa approvazione significa i pazienti diabetici nel Regno Unito possono ricevere il dispositivo EziAutoJector e gli accessori a costo zero attraverso cure finanziate dal NHS.
L'azienda ha instaurato canali di distribuzione tramite un importante grossista farmaceutico sia per farmacie al dettaglio sia online. L'iniziativa comprende programmi educativi rivolti ai professionisti sanitari e un canale di e-commerce diretto al consumatore. In particolare, ogni paziente che passa a EziAutoJector elimina oltre 1.000 aghi insulinici usa egetta all'anno, supportando gli obiettivi ambientali e di efficienza dei costi del NHS.
NuGen Medical Devices (TSXV: NGMD) ha alcanzado un hito importante ya que su socio de distribución en el Reino Unido, EziAutoJector Ltd, recibió la aprobación del NHS Drug Tariff para su dispositivo de administración de insulina sin agujas. Esta aprobación significa que los pacientes diabéticos del Reino Unido pueden recibir el dispositivo EziAutoJector y sus accesorios sin costo a través de la atención financiada por el NHS.
La empresa ha establecido canales de distribución a través de un importante mayorista de productos farmacéuticos tanto para farmacias físicas como para tiendas en línea. La iniciativa incluye programas educativos dirigidos a profesionales de la salud y un canal de comercio electrónico directo al consumidor. Notablemente, cada paciente que cambia a EziAutoJector elimina más de 1.000 agujas de insulina desechables al año, apoyando los objetivos ambientales y de eficiencia de costos del NHS.
NuGen Medical Devices (TSXV: NGMD)는 영국 배포 파트너인 EziAutoJector Ltd가 NHS Drug Tariff의 승인을 받아 바늘 없는 인슐린 투여 기기를 확보했다. 이 승인은 영국의 당뇨병 환자들이 NHS 자금으로 제공되는 치료를 통해 비용 없이 EziAutoJector 기기와 액세서리를 받을 수 있다는 뜻이다.
회사는 대형 제약 도매상을 통해 오프라인 약국과 온라인 약국 모두를 포함하는 배포 채널을 설정했다. 이 이니셔티브에는 의료 전문가를 대상으로 한 교육 프로그램과 소비자 직접 판매를 위한 전자상거래 채널이 포함된다. 특히 EziAutoJector로 전환하는 각 환자는 매년 1,000개가 넘는 일회용 인슐린 주사 바늘을 제거한다는 점이 NHS의 환경 및 비용 효율성 목표를 지원한다.
NuGen Medical Devices (TSXV : NGMD) a franchi une étape importante puisque son partenaire de distribution au Royaume-Uni, EziAutoJector Ltd, a reçu l'approbation NHS Drug Tariff pour son dispositif d'administration d'insuline sans aiguilles. Cette approbation signifie que les patients diabétiques au Royaume-Uni peuvent recevoir l'appareil EziAutoJector et les accessoires sans frais dans le cadre des soins financés par le NHS.
L'entreprise a établi des canaux de distribution via un grossiste pharmaceutique majeur pour les pharmacies physiques et en ligne. L'initiative comprend des programmes éducatifs destinés aux professionnels de santé et un canal de commerce électronique direct au consommateur. Fait notable, chaque patient passant à EziAutoJector élimine plus de 1 000 aiguilles à insuline jetables par an, soutenant les objectifs environnementaux et d'efficacité des coûts du NHS.
NuGen Medical Devices (TSXV: NGMD) hat einen bedeutenden Meilenstein erreicht, da sein britischer Verteilungspartner EziAutoJector Ltd die Genehmigung des NHS Drug Tariff für sein nadelfreies Insulinabgabesystem erhalten hat. Diese Genehmigung bedeutet, dass UK-Diabetespatienten das EziAutoJector-Gerät und Zubehör kostenfrei im NHS-finanzierten Versorgungskontext erhalten können.
Das Unternehmen hat Vertriebswege über einen großen pharmazeutischen Großhändler sowohl für stationäre als auch Online-Apotheken etabliert. Die Initiative beinhaltet Schulungsprogramme für medizinisches Fachpersonal und einen Direct-to-Consumer-E-Commerce-Kanal. Bemerkenswert ist, dass jeder Patient, der zu EziAutoJector wechselt, über 1.000 Einwegspritzen pro Jahr einsparen kann, was NHS-Umwelt- und Kosteneffizienzziele unterstützt.
NuGen Medical Devices (TSXV: NGMD) حققت خطوة مهمة حيث تلقى شريك التوزيع في المملكة المتحدة، EziAutoJector Ltd، موافقة NHS Drug Tariff على جهازه لتوصيل الأنسولين بدون إبر. تعني هذه الموافقة أن يمكن لمرضى السكري في المملكة المتحدة الحصول على جهاز EziAutoJector وملحقاته مجاناً من خلال رعاية ممولة من NHS.
أنشأت الشركة قنوات توزيع من خلال موزع جملة أدوية رئيسي لكلا صيدليات التجزئة والمتاجر عبر الإنترنت. تشمل المبادرة برامج تعليمية تستهدف المهنيين الصحيين وقناة تجارة إلكترونية مباشرة للمستهلك. ومن الجدير بالذكر أن كل مريض ينتقل إلى EziAutoJector سيقضي على أكثر من 1,000 إبرة هلام insulin ذات الاستخدام الواحد سنوياً، وهو ما يدعم أهداف NHS البيئية وكفاءة التكلفة.
NuGen Medical Devices (TSXV: NGMD) 已取得重要里程碑，其英国分销合作伙伴 EziAutoJector Ltd 已获得 NHS Drug Tariff 对其无针注射胰岛素给药装置的批准。这一批准意味着 英国糖尿病患者可以通过 NHS 资助的护理免费获得 EziAutoJector 及其配件。
公司已通过一家主要药品批发商在高街药店和在线药房建立分销渠道。该计划包括面向医疗专业人员的教育项目以及面向消费者的直接电子商务渠道。值得注意的是，每名改用 EziAutoJector 的患者每年将淘汰超过 1,000 根一次性胰岛素针头，有助于 NHS 在环境保护和成本效率方面的目标。
- NHS Drug Tariff approval enables full cost coverage for UK patients
- Established distribution network through major pharmaceutical wholesaler
- Environmental benefit: Eliminates over 1,000 single-use needles per patient annually
- Multiple distribution channels including high-street pharmacies and online services
- None.
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, is pleased to announce that its exclusive UK distribution partner, EziAutoJector® Ltd, has received confirmation from the NHS Business Services Authority, on behalf of the Department of Health, that EziAutoJector® products have been approved for inclusion in the NHS Drug Tariff.
This milestone provides for individuals with diabetes who are prescribed EziAutoJector® by their healthcare provider to receive the EziAutoJector® needle-free insulin delivery device and its accessories at no cost, as part of their NHS-funded diabetes care.
Aligning with the National Institute for Health and Care Excellence (NICE) guidelines, which advocate for personalised patient choice in insulin delivery methods, this should then ensure pharmacists are reimbursed for dispensing the product.
EziAutoJector® Ltd has established supply channels through a major pharmaceutical wholesaler, enabling distribution to both high-street pharmacies and direct-to-patient via online pharmacy services.
EziAutoJector® Ltd's UK market strategy includes targeted educational initiatives designed to engage diabetes healthcare professionals, pharmacists, patients, and caregivers-aimed at increasing awareness, understanding, and advocacy for the EziAutoJector® product range.
Additionally, a direct-to-consumer (D2C) e-commerce channel will support patients in regions where prescribing restrictions currently limit access, ensuring broader availability of the technology.
By transitioning to EziAutoJector®, each patient eliminates the use of over 1,000 single-use insulin needles annually-significantly reducing biohazardous waste and the environmental footprint associated with its collection and disposal. This contributes to a more sustainable approach to diabetes management and supports the NHS in achieving its environmental and cost-efficiency goals.
"NHS reimbursement approval marks a significant step forward for EziAutoJector® Ltd and for NuGen Medical Devices," said Liang Lin, CEO of NuGen Medical Devices. "It enables people living with diabetes to benefit from needle-free insulin delivery and supports clinicians in delivering truly individualised care with reimbursement making easy patient access."
EZIAUTOJECTOR Ltd. www.eziautojector.je
About NuGen Medical Devices
NuGen develops next-generation needle-free devices for subcutaneous drug delivery. Its flagship InsuJet™ system is approved in 42 countries and is designed to improve the lives of millions of people with diabetes worldwide.
Websites: insujet.com | insujet.fr | nugenmd.com
Instagram / X: @NuGenMD | LinkedIn: NuGenMD
Investor Relations: IR@nugenmd.com
For further information, please contact:
Liang Lin, Chief Executive Officer
+ 1-833-867-5557
ir@nugenmd.com
Notice Regarding Forward-Looking Information:
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268223
FAQ
What does the NHS Drug Tariff approval mean for NuGen Medical's EziAutoJector?
How will NuGen Medical (NGMDF) distribute EziAutoJector in the UK market?
What environmental impact does EziAutoJector have compared to traditional insulin delivery?
What is NuGen Medical's strategy for EziAutoJector adoption in the UK?
